Story

Grand Pharmaceutical's FAP-Targeting Cancer Diagnostic Granted FDA Fast Track Designation

ENTHMSVIIDZHZH-TWJAKOHI
Aug 9, 20262 min read
Grand Pharmaceutical's FAP-Targeting Cancer Diagnostic Granted FDA Fast Track Designation
Text size
Background

Grand Pharmaceutical Group Ltd. (00512.HK) announced its investigational radiopharmaceutical, GPN01530-2, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA). The drug is the first diagnostic agent targeting Fibroblast Activation Protein (FAP) for solid tumors to be granted this status, according to the company's announcement.

FDA Designation and Development

The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. Grand Pharma stated that the designation signals regulatory recognition of the drug's potential and could shorten its development and approval timeline.

The company previously received FDA clearance to begin Phase I/II clinical trials for GPN01530-2 as a diagnostic for solid tumors. The Fast Track status marks a significant milestone in its U.S. clinical development program.

The FAP Target and Market Potential

GPN01530-2 is a radiopharmaceutical diagnostic (RDC) that targets Fibroblast Activation Protein (FAP). FAP is highly expressed in over 90% of epithelial tumors but has low expression in healthy tissue, making it a promising and specific target for cancer imaging and therapy.

Sample IUX Markets – In-articleAd

According to Grand Pharma, its drug uses an optimized ligand structure to improve tumor uptake and pharmacokinetic properties. The company reported that early human studies showed superior clinical image contrast and more accurate detection of positive lesions compared to the current standard imaging agent, 18F-FDG.

The potential market for an alternative to 18F-FDG is estimated to be over $5 billion, the source material noted. Citing data from Frost & Sullivan, it also highlighted that the global oncology drug market is projected to reach $702.7 billion by 2035, underscoring the significant commercial opportunity for innovative diagnostics.

Strategic Implications for Grand Pharma

This regulatory milestone positions Grand Pharma as a key competitor in the rapidly growing field of nuclear medicine, particularly in the race to develop FAP-targeted agents. The company is pursuing a "dual filing" strategy to seek regulatory approval in both the United States and China.

Grand Pharma has been building an integrated radiopharmaceutical business, with a pipeline of 16 products in development and global facilities for research and manufacturing. The company aims to leverage this infrastructure to advance GPN01530-2 and other internally developed products for the global oncology market.

Read next

More on Stocks
Back to latest news

LATEST